Moreover, the 36-month beta value for DNLI is 1.43. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DNLI is 124.59M and currently, short sellers hold a 6.40% of that float. On January 31, 2025, DNLI’s average trading volume was 940.63K shares.
DNLI) stock’s latest price update
The stock price of Denali Therapeutics Inc (NASDAQ: DNLI) has surged by 0.73 when compared to previous closing price of 23.41, but the company has seen a 1.29% gain in its stock price over the last five trading sessions. zacks.com reported 2025-01-21 that DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost.
DNLI’s Market Performance
Denali Therapeutics Inc (DNLI) has seen a 1.29% rise in stock performance for the week, with a 14.41% gain in the past month and a -15.12% plunge in the past quarter. The volatility ratio for the week is 4.50%, and the volatility levels for the past 30 days are at 5.95% for DNLI. The simple moving average for the last 20 days is 8.97% for DNLI stock, with a simple moving average of 1.32% for the last 200 days.
Analysts’ Opinion of DNLI
Many brokerage firms have already submitted their reports for DNLI stocks, with Robert W. Baird repeating the rating for DNLI by listing it as a “Outperform.” The predicted price for DNLI in the upcoming period, according to Robert W. Baird is $31 based on the research report published on January 07, 2025 of the current year 2025.
Stifel gave a rating of “Buy” to DNLI, setting the target price at $37 in the report published on December 16th of the previous year.
DNLI Trading at 3.88% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.25% of loss for the given period.
Volatility was left at 5.95%, however, over the last 30 days, the volatility rate increased by 4.50%, as shares surge +16.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.12% lower at present.
During the last 5 trading sessions, DNLI rose by +1.29%, which changed the moving average for the period of 200-days by +29.13% in comparison to the 20-day moving average, which settled at $21.64. In addition, Denali Therapeutics Inc saw 15.70% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from Ho Carole, who sale 12,255 shares at the price of $20.22 back on Jan 06 ’25. After this action, Ho Carole now owns 178,580 shares of Denali Therapeutics Inc, valued at $247,796 using the latest closing price.
Ho Carole, the Chief Medical Officer of Denali Therapeutics Inc, sale 2,907 shares at $20.81 during a trade that took place back on Jan 07 ’25, which means that Ho Carole is holding 175,673 shares at $60,495 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- 1.65 for the present operating margin
- 1.02 for the gross margin
The net margin for Denali Therapeutics Inc stands at 1.4. The total capital return value is set at -0.37. Equity return is now at value -35.09, with -31.77 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -6.91. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -23.94.
Currently, EBITDA for the company is -179.97 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of -11.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.98.
Conclusion
To wrap up, the performance of Denali Therapeutics Inc (DNLI) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
